HIV感染者肺孢子菌肺炎治疗方案疗效与安全性的比较:随机对照试验的系统综述与网状Meta分析
该系统综述与网状Meta分析纳入14项1983至1996年的随机对照试验共1788例HIV感染者,比较肺孢子菌肺炎治疗方案的疗效与耐受性。直接比较中无方案显著优于甲氧苄啶-磺胺甲噁唑(TMP-SMX);网络分析中克林霉素/伯氨喹在治疗失败方面排名最佳,吸入喷他佐辛耐受性最佳,对照药物耐受性均优于TMP-SMX。作者认为应重新评估TMP-SMX作为唯一一线治疗的地位。
要点
- 直接比较中无方案在疗效上显著优于TMP-SMX
- 克林霉素/伯氨喹治疗失败排名最佳(累积排序曲线下面积0.8)
- 吸入喷他佐辛耐受性最佳(累积排序曲线下面积0.9),对照药物耐受性均优于TMP-SMX
核心结论
- 作者认为应重新评估TMP-SMX作为HIV感染者肺孢子菌肺炎唯一一线治疗的地位,因其他治疗方案耐受性更好且疗效相当。
- 在可获得替代药物的地区,作者分析提示替代方案可能提供相当的有效性,当合并症需要时可灵活使用替代治疗。
研究设计与样本
- 系统综述与频率学派网状Meta分析,检索Embase、Medline和CENTRAL自建库至2024年2月3日。
- 纳入至少比较两种肺孢子菌肺炎治疗方案的随机对照试验,研究对象为HIV感染者。
- 共纳入14项1983至1996年间开展的随机对照试验,1788例参与者,27个治疗臂。
- 由两名独立评价者进行标题、摘要和全文筛选及数据提取,使用Cochrane Risk-of-Bias 2工具评估偏倚风险。
主要发现
- 直接比较中无方案在治疗失败方面显著优于TMP-SMX。
- 网络Meta分析中,治疗失败方面克林霉素/伯氨喹排名最佳(累积排序曲线下面积0.8),其次为静脉喷他佐辛(0.8)和TMP-SMX(0.8)。
- 全因死亡方面,直接比较中TMP-SMX优于阿托伐醌,但完整网络分析中无治疗优于其他。
- 死亡降低方面氨苯砜-TMP(0.7)和静脉喷他佐辛(0.8)排名最高。
- 安全性与耐受性方面,对照药物一致优于TMP-SMX,氨苯砜-TMP、吸入喷他佐辛和阿托伐醌的毒性显著降低;吸入喷他佐辛耐受性最佳(0.9),其次为曲美沙特(0.8)和阿托伐醌(0.8)。
临床怎么用
- 作者认为应重新评估TMP-SMX作为HIV感染者肺孢子菌肺炎唯一一线治疗的地位。
- 在可获得替代药物的地区,作者分析提示替代方案可能提供相当的有效性,当合并症需要时可灵活使用替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP. OBJECTIVES: The objectives of this study are to compare the efficacy (treatment failure and mortality) and tolerability (treatment change) of PCP treatment regimens with a frequentist network meta-analysis. DATA SOURCES: Data sources include Embase, Medline, and CENTRAL from inception to 3 February 2024. STUDY ELIGIBILITY CRITERIA: Study eligibility criteria include comparative randomized controlled trials (RCTs) of at least two PCP treatment regimens. PARTICIPANTS: Participants include PWH. INTERVENTIONS: Interventions include treatment regimens for PCP compared head-to-head. ASSESSMENT OF RISK OF BIAS: Assessment of risk of bias includes Cochrane Risk-of-bias tool for RCTs (Cochrane Risk-of-Bias 2). METHODS OF DATA SYNTHESIS: Title, abstract, and full-text screening, along with data extraction, were conducted by two independent reviewers. Data on PCP treatment failure, all-cause mortality, and discontinuation because of toxicity were pooled and ranked. RESULTS: Fourteen RCTs conducted between 1983 and 1996 included 1788 participants across 27 treatment arms. No regimen showed statistically significant superiority over TMP-SMX in direct comparison. In the network meta-analysis, clindamycin/primaquine was ranked the best (surface under the cumulative ranking curve, 0.8), followed by intravenous pentamidine (0.8) and TMP-SMX (0.8) regarding treatment failure. Regarding all-cause mortality, TMP-SMX was superior to atovaquone in direct comparison, but no treatment was superior in the full network analysis. Dapsone-TMP (0.7) and intravenous pentamidine (0.8) were ranked the highest for mortality reduction. For safety and tolerability, comparator drugs consistently outperformed TMP-SMX, with significant reductions in toxicity observed for dapsone-TMP, inhaled pentamidine, and atovaquone. Inhaled pentamidine (0.9) was the best tolerated, followed by trimetrexate (0.8) and atovaquone (0.8). CONCLUSIONS: We conclude that TMP-SMX should be reassessed as the standalone first-line therapy for PCP in PWH, given the better tolerability and comparable efficacy of other treatments. In places with access to alternative drugs for PCP treatment, our analysis suggests that alternative regimens may offer comparable effectiveness, providing flexibility to use alternative treatments when comorbidities necessitate it.
引用
- Hatzl S, Posch F, Scholz L, et al. Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2024. PMID: 39732393. doi:10.1016/j.cmi.2024.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。